MedTrace Logo

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

NCT02489903 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2025-03-17

Study results available
· View outcomes & findings →

Summary

This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen. RRx-001 is administered with autologous blood once weekly followed by or in combination with reintroduction of platinum-based doublet therapy.

Conditions

Interventions

DRUG

RRx-001

DRUG

Cisplatin

DRUG

Etoposide

DRUG

Carboplatin

DRUG

Irinotecan

DRUG

Vinorelbine

DRUG

Doxil

DRUG

Gemcitabine

DRUG

Taxane

DRUG

Paclitaxel

DRUG

Nab-Paclitaxel

DRUG

Pemetrexed

Sponsors & Collaborators

  • EpicentRx, Inc.

    lead INDUSTRY

Principal Investigators

  • Bryan Oronsky, MD, PhD · EpicentRx, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2021-12-06
Completion
2021-12-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02489903 on ClinicalTrials.gov